Key result
Beta-blockers as single or adjuvant therapy for sustained ventricular tachycardia or ventricular fibrillation are reviewed regarding their antiarrhythmic mechanisms and efficacy.
Why the study?
Does beta-blockade improve outcomes in patients with sustained ventricular tachycardia or ventricular fibrillation?
Does beta-blockade improve outcomes in patients with sustained ventricular tachycardia or ventricular fibrillation?
This review summarizes the antiarrhythmic mechanisms and efficacy of beta-blockers in patients with sustained VT or VF, particularly in the context of heart failure.
Answers are grounded in this paper and cite their sources.
May inform beta-blocker use in sustained VT/VF with HF; leaves open need for modern randomized outcome trials.
The value of beta-blockers as antiarrhythmic drugs in patients with sustained VT or VF has received only little attention. This article summarizes the current state of knowledge regarding the identification of patients with sustained VT or VF with the highest benefit of beta-blockade. The antiarrhythmic mechanisms of beta-blockade and its efficacy as single or adjuvant therapy in patients with sustained VT or VF are reviewed. Current insights into the effects of beta-blockade in patients suffering from VT, in particular in the setting of heart failure, are discussed and future directions are considered.
No takes yet. Share an insight, caveat, or question.
Wiesfeld et al. (1996) conducted a review in Sustained ventricular tachycardia or ventricular fibrillation. Beta-blockers was evaluated. Beta-blockers as single or adjuvant therapy for sustained ventricular tachycardia or ventricular fibrillation are reviewed regarding their antiarrhythmic mechanisms and efficacy.
Synapse has enriched 10 related papers. Consider them for comparative context: